Methyl 3-amino-6-methoxythieno [2,3-b] quinoline-2-carboxylate (PU-48) is a novel diuretic urea transporter inhibitor. The aim of this study is to investigate the profile of plasma pharmacokinetics, tissue distribution, and excretion by oral dosing of PU-48 in rats. Concentrations of PU-48 within biological samples are determined using a validated high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. After oral administration of PU-48 (3, 6, and 12 mg/kg, respectively) in self-nanomicroemulsifying drug delivery system (SNEDDS) formulation, the peak plasma concentrations (Cmax), and the area under the curve (AUC0–∞) were increased by the dose-dependent and linear manner, but the marked different of plasma half-life (t1/2) were not observed. This suggests that the pharmacokinetic profile of PU-48 prototype was first-order elimination kinetic characteristics within the oral three doses range in rat plasma. Moreover, the prototype of PU-48 was rapidly and extensively distributed into thirteen tissues, especially higher concentrations were detected in stomach, intestine, liver, kidney, and bladder. The total accumulative excretion of PU-48 in the urine, feces, and bile was less than 2%. This research is the first report on disposition via oral administration of PU-48 in rats, and it provides important information for further development of PU-48 as a diuretic drug candidate.
Detection and endoscopic removal of EGC effectively reduced GC-caused mortality, yet no effective non-invasive screening approaches have been clinically used. Gastric juice integrates tissue- and gastric-microbiome-derived metabolites, making it a promising biofluid for screening EGC. To systematically profile metabolic reprogramming in gastric juice during gastric tumorigenesis, we carried out untargeted metabolic profiling in the discovery cohort enrolling patients at different stages along Correa’s cascade. We identified similar metabolic landscapes between HGD and EGC patients, which significantly differed from those of gastritis and intestinal metaplasia stages. These altered metabolites were subjected to origin analysis, revealing an association of both tumorigenesis-induced tissue metabolic reprogramming and gastric microbiome metabolic reprogramming, as supported by catalytic enzyme changes between tumor and adjacent normal tissues, and by bacteria-derived indole metabolites that correlated with altered gastric bacteria in GC patients. Least absolute shrinkage and selection operator (LASSO) was used for biomarker screening, and the selected metabolites were transferred into MRM-based targeted metabolic detection. A 4-metabolite panel-based diagnostic model was established in the discovery cohort and evaluated in an independent validation cohort, yielding an AUC of 0.90 (90.0% sensitivity, 79.0% specificity), with all three HGD and 20 of 23 EGC cases correctly classified. With the aid of endogastric capsules for non-invasive acquisition of gastric juice, our gastric juice metabolite-based test provides proof-of-concept evidence for its clinical utility in the early detection of GC and precancerous dysplasia.